Paxlovid Does Not Reduce Risk of Long COVID, Potentially Linked to Rebound Symptoms: Study

• Paxlovid Does Not Reduce Risk of Long COVID, Potentially Linked to Rebound Symptoms: Study
  by Amie Dahnke, https://www.theepochtimes.com/health
  Researchers found little difference in outcomes between Paxlovid users and nonusers. They also found 1 in 5 users experienced rebound symptoms.
  –
  Paxlovid, an antiviral medication prescribed to treat symptoms associated with COVID-19, does not reduce the risk of developing long COVID in vaccinated people recovering at home, according to new research.
  –
  That insight comes from a new study published in the Journal of Medical Virology on Jan. 4, 2024. Conducted by a team of researchers from the University of California–San Francisco, the study also found that more people are experiencing rebounds of their COVID symptoms after taking Paxlovid (nirmatrelvir-ritonavir) than previously reported.
  –
  Paxlovid is the first antiviral pill approved by the U.S. Food and Drug Administration (FDA) to treat mild and moderate COVID-19 in adults. It is typically prescribed to those at high risk of having the virus progress to a severe illness, including hospitalization or death. The medication has also been authorized for use in children 12 and older who are at risk of severe outcomes from COVID-19.
  –
  read more.

end